Patent ID: 11884939
Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 10:
11. The engineered attenuated VACV strain of claim 10,
wherein the disrupted C7L gene does not encode a full-length, wild-type gene product; or
wherein the disrupted C7L gene comprises an insertion of a heterologous nucleic acid sequence into the coding sequence of the C7L gene; or
wherein the disrupted C7L gene comprises an insertion of one or more gene cassettes; or
wherein the disrupted C7L gene comprises replacement of at least a portion of the gene with one or more gene cassettes, and optionally wherein the one or more gene cassettes comprise a nucleotide sequence encoding human Fms-like tyrosine kinase 3 ligand (hFlt3L) or wherein the one or more gene cassettes comprise a nucleotide sequence encoding a selectable marker; or
wherein mice infected with the engineered VACV strain have in increased post-infection lifespan compared to mice infected with a corresponding wild-type strain.